Loading clinical trials...

Evaluation of the Efficacy of Xylitol Nasal Spray Against SARS-CoV-2 | Clinical Trials | Clareo Health

WITHDRAWNPHASE3

Evaluation of the Efficacy of Xylitol Nasal Spray Against SARS-CoV-2

A Randomized Placebo Control Trial to Evaluate the Efficacy of Xylitol Nasal Spray vs. Placebo for Acute COVID-19 Infection

NCT04610801•Larkin Community Hospital

View on ClinicalTrials.gov

Summary

The purpose of this study is to assess the efficacy of Xylitol plus Grapefruit Seed Extract (Xlear) nasal spray as an adjunct treatment of COVID-19.

Detailed Description

After being informed about the study and potential risk, all patients giving written informed consent will undergo a brief screening period to determine eligibility for the study. Once eligibility is confirmed, patients who meet the eligibility requirements will be randomized placebo control manner. Patient will be assigned to Xlear (2 puffs per nosetrils, every 3-4 hours a day) or placebo. Patient will be followed for 1 week. Inflammatory markers will be obtained on Day 4 and repeat COVID-19 RT PCR on Day 7. Follow up will be done on Day 14 for all patients.

Eligibility

Age

18 - 90 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•1. Adults of ages 18 to 90 years of both sexes
•2. With positive SARS-CoV-2 carriage confirmed by nasopharyngeal PCR
•3. Signed informed consent
•4. 1- Mild symptoms: Minimum respiratory symptoms or asymptomatic plus positive test
•5. 2- Moderate symptoms: Respiratory symptoms such as cough, mild shortness of breath with mild oxygen desaturation(room air SpO2 \<92% and \>88% or \<88% corrected to \>92% with 2lt of oxygen)

Exclusion Criteria

•1. Patient with very low viral load (threshold cycle \[Ct\] \> 25 per PCR).
•2. Known hypersensitivity to one of the constituents, particularly to xylitol or GSE
•3. Under 18 years of age
•4. Women of childbearing age who are pregnant, breastfeeding mothers, and intend to become pregnant during the study period; unwilling/unable to take a pregnancy test.
•5. Unable to provide informed consent or decline to consent or unwillingness to adhere to the Standard of Care protocol.
•6. Patients with severe symptoms -Hypoxia (SpO2 \<88% not corrected by 2 liter non-concentrated oxygen) plus severe shortness of breath
•7. History of immunodeficiency or are currently receiving immunosuppressive therapy.
•8. Have had a planned surgical procedure within the past 12 weeks.
•9. Already part of this trial, recruited at a different hospital.
•10. Patient unable to perform oro-nasopharyngeal decolonization
+2 more criteria

Locations (2)

Larkin Community Hospital Palm Springs Campus

Miami, Florida, United States

Larkin Community Hospital

Miami, Florida, United States

Key Dates

Start Date

December 8, 2021

Primary Completion Date

June 8, 2022

Completion Date

August 8, 2022

Last Updated

October 16, 2023

Conditions

Covid19

Interventions

Nasal Spray

DRUG

The Effect of the Covid-19 Pandemic Among Operated Patients

NCT04525716

Covid19Surgery

View study

RECRUITINGPHASE3

The VITDALIZE Study: Effect of High-dose Vitamin D3 on 28-day Mortality in Adult Critically Ill Patients

NCT03188796

Critical IllnessVitamin D Deficiency+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 16, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Evaluation of the Efficacy of Xylitol Nasal Spray Against SARS-CoV-2

Inclusion Criteria

Exclusion Criteria

The Effect of the Covid-19 Pandemic Among Operated Patients

The VITDALIZE Study: Effect of High-dose Vitamin D3 on 28-day Mortality in Adult Critically Ill Patients

Covid-19 and Influenza Oral Vaccine Study

Conversations You Want About Corona Virus Disease (COVID-19)

Lung Function, Exercise Capacity, and Serology Responses in Patients With COVID-19

COVID-19 Risk Assessment for Hospitalization Outcomes and Epidemiology Efficacy